The abstract is read at the publisher; the summary is JClub's.
Perioperative camrelizumab plus chemotherapy improved 2-year event-free survival to 77.8% versus 46.1% in resectable stage III–IVB head and neck squamous cell carcinoma.
- Why it matters: Recurrence is common after multimodal care for resectable locally advanced HNSCC, and it remains uncertain whether perioperative chemoimmunotherapy can improve durable outcomes.
- What they did: In the CAMORAL phase 2 randomized trial in China, 125 untreated patients (18–75) received either neoadjuvant-adjuvant camrelizumab plus albumin-bound paclitaxel/carboplatin with surgery and risk-adapted therapy, or upfront surgery with standard risk-adapted adjuvant therapy.
- The result: The hazard ratio for 2-year EFS was 0.34 (95% CI, 0.17–0.68; P=.001), with higher MPR (47.6%) and pCR (25.4%) in the perioperative group and grade 3+ adverse events in 79.4% versus 56.5%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.